Scholar Rock Holding Corporation Common Stock

SRRKNASDAQ • USD
43.18 USD
↘ 0.03 (0.06%)🟢LIVE (AS OF 09:46 AM EST)
🟢Market: OPEN

Scholar Rock Holding Corporation Common Stock (SRRK) is currently trading at $43.18. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, SRRK is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Nov 13, 2026.

Open?$43.15
High?$43.54
Low?$42.70
Prev. Close?$43.21
Volume?107.9K
Avg. Volume?1.7M
VWAP?$43.12
Rel. Volume?0.06x
Bid / Ask
Bid?$36.76 × 100
Ask?$50.16 × 100
Spread?$13.40
Midpoint?$43.46
Valuation & Ratios
Market Cap?5.3B
Shares Out?122.0M
Float?109.2M
Float %?89.7%
P/E Ratio?N/A
P/B Ratio?31.25
EPS?-$3.39
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Employees
289
Market Cap
5.3B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2018-05-24
Address
301 BINNEY STREET
CAMBRIDGE, MA 02142
Phone: 857-259-3860
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
94
Momentum?
50
Short Sent.?
34
Piotroski F-Score?0/9Weak
Altman Z-Score?4.24Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.50%Squeeze Risk
Short Interest?23.5M
Days to Cover?13.6
Free Float109.2M
Avg Daily Volume1.7M
Settlement Date2026-10-30
Financial Health
Current Ratio?5.41Strong
Quick Ratio?5.40Strong
Cash Ratio?4.57Strong
Debt/Equity?1.16Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
31.25HIGH▾
P/S?
Peers
100
S&P
3
9,248.80HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-12.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
8,950.45HIGH▾
Returns & Efficiency
ROE?
S&P
3
-245.2%WEAK▾
ROA?
S&P
3
-92.7%WEAK▾
Cash Flow & Enterprise
FCF?$-309913000
Enterprise Value?$5.1B
Fundamentals ratios updated end of day